Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.
📥 bit.ly/3syfvGd
Standing room only! 👏
Paulina Rolska-Wójcik and Jessica Griffiths, members of our value and access consulting team, presented a HEOR Theater session on the new EU HTA regulation in front of an overflow crowd at #ISPOREurope.
1
309
The first day of #ISPOREurope has been a huge success!
Our staff in attendance snapped this group photo as they were preparing to welcome clients to the evening reception.
Stop by and see us at booth C2-001 tomorrow!
232
We're just a few days away from #ISPOREurope! We're excited to attend this year's event with @corevitasdata, Thermo Fisher Scientific's latest acquisition that enhances our #RWD and #RWE solutions.
Meet us at booth C2-001, or schedule a chat with us. » bit.ly/3u1tSnx
179
Market approval does not guarantee commercial or clinical success. Regulatory considerations, #patientadherence and inflexible clinical workflows can hinder product uptake.
Our cutting-edge #implementationscience services can help address these barriers » bit.ly/3KcqStx
144
Join our webinar on 7 November to explore the benefits and challenges of collecting #realworlddata (RWD) in continued and #earlyaccessprograms.
Register today! » bit.ly/3u2yvxk
115
How will new European Union (EU) health technology assessment (#HTA) regulations commencing in 2025 impact your cell and gene therapy (CGT) submission?
We have your answers. » bit.ly/44NRZnz
117
Discover how #healtheconomic models play a pivotal role in product development, from early planning through analyses.
Register for this upcoming expert webinar to gain valuable insights. » bit.ly/3rC31gV
1
107
With OncoLocator data, insights into cancer treatments are endless.
Gaining a global understanding of standard of care. Evaluating #earlyphase assets and beyond. OncoLocator is more than data — it’s data smarter.
📈 bit.ly/3DnYfpj
#realworldevidence #realworlddata
91
Many #noveltherapies fail to get integrated into real-world clinical practice.
It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » bit.ly/3KcqStx
1
93
Regulation (EU) 2021/2282 commences in January 2025 for #oncology and #ATMPs and will be fully implemented by 2030.
Discover how our value & access consultants can aid your European #marketaccess. » bit.ly/3Ecy85f
Gain real-time understanding of cancer treatment patterns with unmatched data relevance. ➠ bit.ly/3DnYfpj
#realworlddata
89
Regulation (EU) 2021/2282 starts in January 2025 for #oncology and #ATMPs, with full implementation by 2030.
Learn how our value & access consultants can help you prepare for market access in Europe. » bit.ly/3Ecy85f
120
Our iValue Suite™ helps create best-in-class value stories, global value dossiers, #HTA submissions, payer communication decks and objection handlers.
Contact us today to schedule a demo. » bit.ly/45HcIsK
108
Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.
📥 bit.ly/3syfvGd
117
Our experts advise using a framework to assess options for transformative medicines in order to maximize the value of #IntegratedScientificAdvice. But, that's not always easy.
Let our insights guide you. » bit.ly/3E4oPEk
#patientaccess #consulting #scientificadvice
1
80
What is driving the future of #realworldevidence?
Learn more from our blog, in which our thought leaders outline six key trends, including #realworlddata, #marketaccess, cross-industry collaboration initiatives and more. » bit.ly/43ZU6Tq
53
Evidera retweeted
We’re excited to announce the completion of the acquisition of @corevitasdata. CorEvitas provides insight to the life sciences industry that improves patient care and clinical outcomes, and together we will expand our clinical research services.
OncoLocator™ examines geographic differences in treatment across the most prevalent cancer indications in #womenshealth.
Would you like to explore more? Contact us for a free flat file sample and demo presentation. » bit.ly/47nAL1t
#niraparib #olaraparib #bevacizumab
92
Many #noveltherapies fail to get integrated into real-world clinical practice.
It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » bit.ly/3KcqStx
73























